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patent applications, and regulatory quality have been controlled for. Negative impacts 
of the recent reforms on R&D expenditures for Germany and Norway and, in some 
instances, for Italy and Japan are detected. A positive impact of the 2003 reform on 
R&D related indicators has been found for the US. The reforms reduced R&D expen-
ditures by 0.76% for Italian ﬁrms, decreased R&D intensity of Norwegian ﬁrms by 
2.42%, lowered cash ﬂows of French ﬁrms by 0.72%, but increased the R&D of 
American ﬁrms by 0.27%. These results can be explained by the degree of the reform 
rigidness for price and reimbursement controls, drug development lags, the importance 
of R&D for competition and ﬁrm valuation, and growing exports to less regulated 
markets. The results can also be explained with a theoretical R&D reproduction cycle 
model. CONCLUSIONS: Stronger shifts to more rigid cost-containment reimburse-
ments impeded R&D expenditures. However, despite the adverse regulatory shocks, 
most ﬁrms’ R&D related indicators tend to be persistent in the short run.
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BY ANY OTHER NAME SMELL AS SWEET?
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OBJECTIVES: We investigated the impact of eliminating brand name drug coverage 
on statin drug spending, adherence, and physiologic outcomes in a cohort of Medicare 
beneﬁciaries, compared with a concurrent control group of beneﬁciaries with coverage 
of both brand and generic drugs. METHODS: All subjects were age 65 years. In 
2002–03, beneﬁciaries with restricted coverage had an annual drug beneﬁt cap of 
$1,000; in 2004–05, these beneﬁciaries lost brand name drug coverage, but had no 
coverage limits for generics. Controls had no restrictions or changes in brand/generic 
coverage 2002–05. We used ﬁxed-effects regression models to examine the association 
between coverage and quarterly outcomes. We adjusted for time-varying covariates 
including time, comorbidity (DxCG scores), plus time*coverage interactions. 
RESULTS: The 66,051 subjects had a mean age of 73.6 years, and 50% were female. 
In 2002, 53% of subjects had restricted beneﬁts, and the remaining had no drug beneﬁt 
restrictions. Compared to those with unrestricted beneﬁts and after multivariate adjust-
ment, subjects with restricted beneﬁts had less spending on and worse adherence to 
statin drugs, and worse LDL levels, particularly after the elimination of brand drug 
coverage: for example, statin drug spending differences were $35/quarter (95%CI: 
$32–37); the odds ratio of non-adherence was 1.27 (95% CI:1.19–1.36); and LDL 
differences were 2.00 mg/dL (95% CI:1.65–2.34 mg/dL) for subjects with restricted 
vs. unrestricted coverage, in Q4 2004 vs. Q1 2002. The LDL differences were related 
primarily to reductions in the prescribed daily dose among those with restricted cover-
age; in 2003, 10% of subjects had prescriptions above the maximum recommended 
dose of lovastatin, the only available generic during the study period. CONCLUSIONS: 
Prescription drugs within a therapeutic class are not all clinically equivalent, even 
within narrow classes with few differences such as statins. Careful attention is needed 
to the clinical needs of individual patients when imposing drug coverage restrictions.
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OBJECTIVES: Most published cost-effectiveness analyses related to depression have 
used Markov models. However, evidence shows that probabilities of relapse and 
remission of depressive episodes are time and past events dependent, suggesting the 
appropriateness of discrete event simulation models (DESM). Our aim was to assess 
the cost-effectiveness of agomelatine in major depression from the Portuguese societal 
perspective using a DESM. METHODS: Sequential time to remission and time to 
relapse/recurrence were sampled from weibull distributions. Remission rates were 
obtained from a meta-analysis of randomized, venlafaxine-controlled clinical trials 
with either agomelatine, escitalopram, ﬂuoxetine, paroxetine or sertraline. Probability 
of relapse/recurrence was assumed dependent on the number of previous depressive 
episodes and time since last remission. We compared agomelatine 25 mg/day with 
possible dose titration to a mixed comparator composed by escitalopram(12 mg/- 
day), ﬂuoxetine(38 mg/day), paroxetine(25 mg/day), sertraline(116 mg/day) and 
venlafaxine(150 mg/day), weighted according to the deﬁned daily doses consumed 
between January and June 2008. Only direct costs were considered (drugs, medical 
visits, side effects treatments and monitoring). Effectiveness was measured in quality-
adjusted life years (QALY) and life years in remission (LYR). Time horizon varied 
from 6 to 37 months according to each individual simulation characteristics. When 
appropriate discount rates of 5%/year were applied to costs and effectiveness. 
RESULTS: A gain of 9.4 QALY (95%CI:[6.2;12.4]) or 10 LYR (95%CI:[5.2;15]) was 
estimated for each 100 patients treated with agomelatine. The estimated incremental 
cost of agomelatine treated patients was a325 (95%CI:[167; 827]). Corresponding 
incremental cost-effectiveness ratios were a3460/QALY or a3197/LYR. Probabilistic 
sensitivity analysis revealed 11% probability of agomelatine dominance and 97.5% 
of being cost-effective at a threshold of a10,000, regardless of the effectiveness measure 
considered. CONCLUSIONS: DESM is a valuable tool to model the cost-effectiveness 
of major depression. Agomelatine is a cost-effective drug for the treatment of major 
depressive disorder in Portugal, when compared to current clinical practice.
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OBJECTIVES: Depression causes a large burden of disease worldwide. Effective pre-
vention has the potential to reduce that burden considerably. We investigated the 
cost-effectiveness of minimal contact psychotherapy, based on Lewinson’s ‘Coping 
with depression’ course, targeted at opportunistically screened individuals with sub-
threshold (minor) depression. METHODS: We compared the costs and effects of an 
intervention scenario (all persons in the target population are screened and those with 
sub-threshold depression receive preventive minimal contact psychotherapy) with a 
current practice scenario. Using a Markov model, future health effects and costs were 
estimated from both the health care and the societal perspective. Incremental cost 
effectiveness ratios (ICER) were expressed in euro per DALY averted. Costs were dis-
counted at 4% and effects at 1.5%. The time horizon was ﬁve years. Probabilistic 
sensitivity analysis was employed to study the effect of uncertainty in the model 
parameters. RESULTS: From the health care perspective the incremental cost-
 effectiveness ratio was a4000 per DALY, and from the societal perspective the inter-
vention was even cost saving. CONCLUSIONS: This modeling study showed that 
from a health care perspective health gains can be achieved at a low cost if opportu-
nistic screening for sub-threshold depression in combination with MCP is implemented 
in a primary care setting. From a societal perspective, the modeled strategy of depres-
sion prevention is even cost saving.
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The association between the use of some antipsychotic drugs and diabetes mellitus is 
still controversial. OBJECTIVES: To assess the risk of diabetes mellitus in new users 
of antipsychotic drugs. METHODS: A nested case-control study using the Quebec 
Health Insurance Board databases. The source cohort was made of diabetes-free 
people who initiated antipsychotic treatment between January 1, 2000 and march 31, 
2007. Cases were cohort members who initiated antidiabetic treatment or had a 
diagnosis of diabetes during their follow-up period. Ten matched (for sex, age, year 
of treatment initiation) controls were selected using density sampling method. A 6-
value variable was used to assess exposure to antipsychotic: any typical, clozapine, 
olanzapine, quetiapine, risperidone or more than one drug. A paired multivariate 
logistic regression model was used to calculate adjusted odds ratios (OR). Co-variates 
included current user status, number of days of exposure to antipsychotic treatment, 
patient characteristics, use of other drugs and of health services. RESULTS: Among 
the 67,515 individuals included in the cohort, 1,715 cases of diabetes were identiﬁed 
and were matched to 17,143 controls. No difference was observed across atypical 
antipsychotic users. Longer exposure to any antipsychotic treatment was associated 
with diabetes [OR for each 30-day period: 1.05 (CI: 1.03–1.07)]. Individuals living in 
an urban area, those with low SES, those in the two highest tertiles of the number of 
different drugs used and of the number of medical visits, those who had been hospital-
ized, and those exposed q80% of the time period to drugs others than antipsychotic 
that can increase the risk of diabetes were more likely to develop the disease [OR: 
1.23 (CI: 1.03–1.46)]. CONCLUSIONS: Duration of exposure to antipsychotic treat-
ment is associated with diabetes, regardless of atypical antipsychotic agent. One limita-
tion to this analysis is that aripiprazole and ziprasidone were not available and thus 
no conclusion can be drawn.
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OBJECTIVES: To evaluate the impact of T2DM with comorbid depression on Patient 
Reported Outcomes (PROs) and health care resource use in France, Germany Italy, 
Spain and the UK. METHODS: Data were from respondents self-reporting diagnosis 
of T2DM in the 2008 U.S. National Health and Wellness Survey (NHWS), an annual 
cross-sectional survey of health care attitudes, behaviors, disease states, and outcomes 
of adults aged 18. Depression symptoms were deﬁned by afﬁrmative responses in the 
past month to: bothered by feeling down, depressed or hopeless and bothered by 
having little interest or pleasure in doing things. Outcomes included health care utiliza-
tion in the past six months and SF-12v2 summary scores. Regression models assessed 
independent effects of depression on outcomes and resource use, adjusting for gender, 
age, country, marital status, education, and an adjusted Charlson Comorbidity Index 
score. RESULTS: Among 2,668 respondents diagnosed with T2DM, 828 (31%) were 
female and 750 (28%) experienced symptoms of depression. After controlling for 
covariates, patients with comorbid depression had lower SF-12v2 physical and mental 
summary scores of 5.3 (p  0.0001) and 15.7 (p  0.0001), respectively; however, 
